Acceleron Pharma Inc (XLRN) 38.02 $XLRN
Celgene Corp.'s Expanding Margins
Brian Orelli, The Motley Fool - Motley Fool - Thu Jan 29, 1:46PM CST
Celgene 's fourth-quarter earnings can be a bit of a snoozer because the company typically reports preliminary revenue and earnings numbers at JP Morgan 's healthcare conference earlier in January. This year was no different, but we did get some...
JPM: 59.67 (+0.10), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), CELG: 115.88 (+0.16)
Acceleron Pharma to Present at Upcoming Investor Conferences in February
Business Wire - Wed Jan 28, 6:00AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will participate in the following upcoming investor conferences.
XLRN: 38.02 (+0.07)
5 Cant-Miss Reasons Why Celgene Corporation Could Soar
Todd Campbell, The Motley Fool - Motley Fool - Mon Jan 26, 7:04AM CST
Source: Celgene Corporation Celgene Corporation 's slate of top selling medicines already makes it one of biotech's biggest success stories, but Celgene's recent long-term forecast suggests that the company's best days are ahead of it. Here are...
BLUE: 90.70 (+0.93), JNJ: 99.62 (+1.18), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), CELG: 115.88 (+0.16)
5 Tiny Biotech Stocks to Own in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 17, 5:51AM CST
Biotech stocks are among the market's riskiest, but investors willing to accept the potential for pipeline failure might consider owning these five small-cap biotech stocks in 2015. All five have intriguing therapies in late-stage clinical trials,...
JNJ: 99.62 (+1.18), INSY: 51.50 (-0.66), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16), XLRN: 38.02 (+0.07)
Insider Trading Alert - XLRN, MOH And PF Traded By Insiders
at The Street - Wed Jan 14, 1:00PM CST
Stocks with insider trader activity include XLRN, MOH and PF
PF: 36.18 (-0.21), MOH: 59.66 (+0.26), XLRN: 38.02 (+0.07)
Acceleron Pharma Outlines Corporate Objectives for 2015
Business Wire - Mon Jan 12, 6:00AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its major corporate research and development objectives for 2015. Acceleron has four internally discovered and developed investigational protein therapeutics in human clinical trials and expects all four molecules to be in either phase 2 or phase 3 clinical trials by the end of 2015.
XLRN: 38.02 (+0.07)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 90.70 (+0.93), ACT: 285.37 (+3.71), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), EPZM: 21.58 (+0.08), ALKS: 71.40 (-1.89), HSP: 87.35 (unch), CELG: 115.88 (+0.16), JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17)
Adimab Announces New Partnerships with Acceleron, Oncothyreon, Surface Oncology and Potenza
Business Wire - Fri Jan 09, 8:45AM CST
Adimab, LLC, the technology leader in the discovery of monoclonal and bispecific antibodies, today announced independent discovery collaborations with Acceleron Pharma, Inc., Oncothyreon, Inc., Surface Oncology and Potenza Therapeutics, Inc. All four collaborations are structured as funded discovery programs in which Adimab will discover and optimize therapeutic monoclonal or bispecific antibodies against multiple targets for each partner.
MRK: 58.81 (-0.07), ONTY: 1.57 (unch), XLRN: 38.02 (+0.07)
Vericel Corporation Names Three New Board Members
Marketwired - Wed Jan 07, 7:45AM CST
Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the appointment of three new members to the company's board of directors: Steven C. Gilman, Ph.D., executive vice president and chief scientific officer of Cubist Pharmaceuticals; Kevin F. McLaughlin, senior vice president and chief financial officer of Acceleron Pharma; and Paul Wotton, Ph.D., president and chief executive officer of Ocata Therapeutics.
CBSTZ: 0.06 (unch), VCEL: 3.71 (-0.01), XLRN: 38.02 (+0.07)
Minerva Neurosciences' MIN-301 Positive in Primate Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 6:20PM CST
Minerva Neurosciences, Inc. (NERV) announced positive results from the Primomed study in non-human primates on its investigational compound, MIN-301.
NERV: 4.68 (+0.09), INCY: 75.94 (+0.28), RGDO: 1.17 (+0.02), XLRN: 38.02 (+0.07)
These 3 Biotechs Are Looking at a Happy New Year
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 31, 11:33AM CST
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year. If your portfolio could use some exposure to healthcare and biotechs, join the Fool's...
NFLX: 466.10 (+9.37), MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), AMZN: 381.83 (+4.66), JPM: 59.67 (+0.10), GILD: 101.90 (+1.10), AGIO: 118.55 (+0.11), AAPL: 127.08 (+0.62), XLRN: 38.02 (+0.07), CELG: 115.88 (+0.16)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 137.61 (-0.54), SKBI: 4.22 (+0.03), PTBI: 3.10 (unch), FMD: 5.45 (-0.16), GHC: 976.65 (+15.51), VRML: 2.08 (+0.12), ADBE: 76.51 (+1.92), OHAI: 4.67 (+0.01), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), LII: 104.27 (+0.88), JAZZ: 169.69 (+6.89), NMBL: 23.19 (+0.81), REGN: 402.40 (+0.66), OAS: 16.84 (-0.03), XLRN: 38.02 (+0.07), SYK: 94.51 (+1.14), CRM: 62.85 (+1.59)
Commit To Purchase Acceleron Pharma At $30, Earn 16.7% Annualized Using Options
at The Street - Wed Dec 24, 11:20AM CST
Investors considering a purchase of Acceleron Pharma, Inc. shares, but tentative about paying the going market price of $39.00/share, might benefit from considering selling puts among the alternative strategies at their disposal.
XLRN: 38.02 (+0.07)
Myelofibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/5dgl3c/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca PLC - Eli Lilly and Company - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Celgene Corporation - Incyte Corporation - Geron Corporation - MEI Pharma, Inc. - Threshold Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/5d...lofibrosis
GILD: 101.90 (+1.10), GERN: 3.03 (unch), INCY: 75.94 (+0.28), AZN: 69.96 (+0.20), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Acceleron Pharma Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 7:00AM CST
Acceleron Pharma Inc. (NASDAQ: XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it has been selected for addition to the NASDAQ Biotechnology Index(R) (NASDAQ: NBI), effective Monday, December 22, 2014.
XLRN: 38.02 (+0.07)
Acceleron Pharma elects Dr. Francois Nader to its board
M2 - Mon Dec 15, 6:22AM CST
Biopharmaceutical company Acceleron Pharma (NasdaqGM:XLRN) disclosed on Friday the addition of Dr. Francois Nader, M.D., M.B.A, to its board of directors.
XLRN: 38.02 (+0.07)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors
Business Wire - Fri Dec 12, 6:30AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Francois Nader, M.D., M.B.A, to its Board of Directors.
XLRN: 38.02 (+0.07)
Celgene Corp.'s Expanding Margins
Brian Orelli, The Motley Fool - Motley Fool - Thu Jan 29, 1:46PM CST
Celgene 's fourth-quarter earnings can be a bit of a snoozer because the company typically reports preliminary revenue and earnings numbers at JP Morgan 's healthcare conference earlier in January. This year was no different, but we did get some...
JPM: 59.67 (+0.10), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), CELG: 115.88 (+0.16)
Acceleron Pharma to Present at Upcoming Investor Conferences in February
Business Wire - Wed Jan 28, 6:00AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will participate in the following upcoming investor conferences.
XLRN: 38.02 (+0.07)
5 Cant-Miss Reasons Why Celgene Corporation Could Soar
Todd Campbell, The Motley Fool - Motley Fool - Mon Jan 26, 7:04AM CST
Source: Celgene Corporation Celgene Corporation 's slate of top selling medicines already makes it one of biotech's biggest success stories, but Celgene's recent long-term forecast suggests that the company's best days are ahead of it. Here are...
BLUE: 90.70 (+0.93), JNJ: 99.62 (+1.18), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), CELG: 115.88 (+0.16)
5 Tiny Biotech Stocks to Own in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 17, 5:51AM CST
Biotech stocks are among the market's riskiest, but investors willing to accept the potential for pipeline failure might consider owning these five small-cap biotech stocks in 2015. All five have intriguing therapies in late-stage clinical trials,...
JNJ: 99.62 (+1.18), INSY: 51.50 (-0.66), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16), XLRN: 38.02 (+0.07)
Insider Trading Alert - XLRN, MOH And PF Traded By Insiders
at The Street - Wed Jan 14, 1:00PM CST
Stocks with insider trader activity include XLRN, MOH and PF
PF: 36.18 (-0.21), MOH: 59.66 (+0.26), XLRN: 38.02 (+0.07)
Acceleron Pharma Outlines Corporate Objectives for 2015
Business Wire - Mon Jan 12, 6:00AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its major corporate research and development objectives for 2015. Acceleron has four internally discovered and developed investigational protein therapeutics in human clinical trials and expects all four molecules to be in either phase 2 or phase 3 clinical trials by the end of 2015.
XLRN: 38.02 (+0.07)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 90.70 (+0.93), ACT: 285.37 (+3.71), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), EPZM: 21.58 (+0.08), ALKS: 71.40 (-1.89), HSP: 87.35 (unch), CELG: 115.88 (+0.16), JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17)
Adimab Announces New Partnerships with Acceleron, Oncothyreon, Surface Oncology and Potenza
Business Wire - Fri Jan 09, 8:45AM CST
Adimab, LLC, the technology leader in the discovery of monoclonal and bispecific antibodies, today announced independent discovery collaborations with Acceleron Pharma, Inc., Oncothyreon, Inc., Surface Oncology and Potenza Therapeutics, Inc. All four collaborations are structured as funded discovery programs in which Adimab will discover and optimize therapeutic monoclonal or bispecific antibodies against multiple targets for each partner.
MRK: 58.81 (-0.07), ONTY: 1.57 (unch), XLRN: 38.02 (+0.07)
Vericel Corporation Names Three New Board Members
Marketwired - Wed Jan 07, 7:45AM CST
Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the appointment of three new members to the company's board of directors: Steven C. Gilman, Ph.D., executive vice president and chief scientific officer of Cubist Pharmaceuticals; Kevin F. McLaughlin, senior vice president and chief financial officer of Acceleron Pharma; and Paul Wotton, Ph.D., president and chief executive officer of Ocata Therapeutics.
CBSTZ: 0.06 (unch), VCEL: 3.71 (-0.01), XLRN: 38.02 (+0.07)
Minerva Neurosciences' MIN-301 Positive in Primate Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 6:20PM CST
Minerva Neurosciences, Inc. (NERV) announced positive results from the Primomed study in non-human primates on its investigational compound, MIN-301.
NERV: 4.68 (+0.09), INCY: 75.94 (+0.28), RGDO: 1.17 (+0.02), XLRN: 38.02 (+0.07)
These 3 Biotechs Are Looking at a Happy New Year
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 31, 11:33AM CST
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year. If your portfolio could use some exposure to healthcare and biotechs, join the Fool's...
NFLX: 466.10 (+9.37), MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), AMZN: 381.83 (+4.66), JPM: 59.67 (+0.10), GILD: 101.90 (+1.10), AGIO: 118.55 (+0.11), AAPL: 127.08 (+0.62), XLRN: 38.02 (+0.07), CELG: 115.88 (+0.16)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 137.61 (-0.54), SKBI: 4.22 (+0.03), PTBI: 3.10 (unch), FMD: 5.45 (-0.16), GHC: 976.65 (+15.51), VRML: 2.08 (+0.12), ADBE: 76.51 (+1.92), OHAI: 4.67 (+0.01), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), LII: 104.27 (+0.88), JAZZ: 169.69 (+6.89), NMBL: 23.19 (+0.81), REGN: 402.40 (+0.66), OAS: 16.84 (-0.03), XLRN: 38.02 (+0.07), SYK: 94.51 (+1.14), CRM: 62.85 (+1.59)
Commit To Purchase Acceleron Pharma At $30, Earn 16.7% Annualized Using Options
at The Street - Wed Dec 24, 11:20AM CST
Investors considering a purchase of Acceleron Pharma, Inc. shares, but tentative about paying the going market price of $39.00/share, might benefit from considering selling puts among the alternative strategies at their disposal.
XLRN: 38.02 (+0.07)
Myelofibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/5dgl3c/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca PLC - Eli Lilly and Company - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Celgene Corporation - Incyte Corporation - Geron Corporation - MEI Pharma, Inc. - Threshold Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/5d...lofibrosis
GILD: 101.90 (+1.10), GERN: 3.03 (unch), INCY: 75.94 (+0.28), AZN: 69.96 (+0.20), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Acceleron Pharma Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 7:00AM CST
Acceleron Pharma Inc. (NASDAQ: XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it has been selected for addition to the NASDAQ Biotechnology Index(R) (NASDAQ: NBI), effective Monday, December 22, 2014.
XLRN: 38.02 (+0.07)
Acceleron Pharma elects Dr. Francois Nader to its board
M2 - Mon Dec 15, 6:22AM CST
Biopharmaceutical company Acceleron Pharma (NasdaqGM:XLRN) disclosed on Friday the addition of Dr. Francois Nader, M.D., M.B.A, to its board of directors.
XLRN: 38.02 (+0.07)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors
Business Wire - Fri Dec 12, 6:30AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Francois Nader, M.D., M.B.A, to its Board of Directors.
XLRN: 38.02 (+0.07)
